Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant p...
Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different prognoses is unknown.
Methods
We conducted a retrospective cohort study of men in a national healthcare de...
Alternative Titles
Full title
Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e87d252553e64f07b78df5cbebfcca3e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e87d252553e64f07b78df5cbebfcca3e
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.7334
